Mandate

Vinge represents Solidium in connection with SSAB’s combination with Rautaruukki

January 24, 2014

SSAB AB (publ) (NASDAQ OMX Stockholm) has made a recommended public share exchange offer for Rautaruukki Oyj (NASDAQ OMX Helsinki). Rautaruukki’s largest shareholder is Solidium Oy, which is wholly owned by the State of Finland. Upon completion of the combination, Solidium will become a major shareholder of the combined group, together with SSAB’s current largest shareholder, Industrivärden. The total value of the share exchange offer amounts to SEK 10.1 billion (EUR 1.1 billion). 

Vinge represents Solidium in matters relating to Swedish law. The Vinge team consists of capital markets and public M&A partners Göran Nyström and Erik Sjöman

Related

Vinge advises Aspo on its acquisition of Swed Handling

Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024